Form 4: Coya Therapeutics Director Wilbur L. Ross Jr. Reports Stock Option Grant

Director Wilbur L. Ross Jr. reports acquisition of stock options in Coya Therapeutics, Inc.

Summary

• On February 25, 2025, Wilbur L. Ross Jr., a director of Coya Therapeutics, Inc., reported the acquisition of stock options.
• The stock options grant the right to buy 5,000 shares of common stock at an exercise price of $5.97.
• The options vest 100% on the first anniversary of the grant date, subject to continuous service.
• The options expire on February 25, 2035.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating a standard compensation practice. It doesn't inherently convey strong positive or negative sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, as it encourages continued service and commitment to the company's long-term success.
• Comparable companies like BioNTech or Moderna also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's efforts contribute to the company's success.
• The grant incentivizes the director to act in the best interests of the company and its shareholders.

Key Dates